ImmunogenicitySafety and Cross - Immune Response With Mutant Strains of the Third Dose Using Inactivated COVID-19 Vaccine in Population Aged 18 Years and Above

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Aluminium hydroxide
Indications COVID 2019 infections
Focus Pharmacodynamics
Sponsors Sinovac Biotech

05 Nov 2023 Planned End Date changed from 20 Apr 2023 to 20 Feb 2024.
11 Jul 2022 Status changed from not yet recruiting to active, no longer recruiting.
19 Apr 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com